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Abstract
Objective: To investigate the prevalence of detectable
jugular lymphatic sacs in a setting for first trimester
screening for Down syndrome, and to evaluate the influ-
ence of jugular lymphatic sacs on the screening perform-
ance for chromosomal abnormalities.
Methods: A prospective single center study (Erasmus
University Medical Center, Rotterdam, The Netherlands)
over a period of one year (January 2003–February 2004).
First trimester nuchal translucency measurement was
performed in a study population of 415 fetuses. Addi-
tionally, the transversal plane with the spine and mandi-
ble was visualized to verify the presence of jugular
lymphatic sacs. The jugular lymphatic sacs were meas-
ured anterior-posterior. The association between nuchal
translucency and jugular lymphatic sacs was tested.
Results: Follow-up was complete in 406 cases (97.8%).
Jugular lymphatic sacs could be visualized in 98 out of
415 (23.5%). The nuchal translucency thickness and the
mean of the left and right jugular lymphatic sac were sig-
nificantly correlated.
Conclusion: The sonographic visualization of jugular
lymphatic sacs significantly predicts chromosomal
abnormalities, although nuchal translucency is a better
predictor. Nuchal translucency and jugular lymphatic
sacs are strongly correlated and therefore not applicable
in a combination test.
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screening; jugular lymphatic sacs; nuchal translucency;
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Introduction
First trimester measurement of nuchal translucency (NT)
with maternal blood sampling is standard antenatal care
in the Netherlands. This screening strategy is a sensitive
method for the identification of fetuses at risk of aneu-
ploidy w13, 18x and is associated with increased risk of
genetic syndromes and fetal structural malformations
w14, 15x. Although many theories have been proposed, a
common morphogenesis explaining the interrelationship
between the complete spectrum of fetal malformations
and enlarged nuchal translucency is still lacking. Previous
studies demonstrated abnormal developed jugular lym-
phatic sacs (JLS) in combination with an enlarged NT w1,
5–7x. Since a disturbance in the lymphangiogenesis pre-
cedes the development of an increased NT w5, 7x, it is
hypothesized that JLS size could be an earlier and better
predictor of chromosomal abnormalities.
We conducted an observational study to investigate
the prevalence of detectable JLS and to evaluate the test
performance by adding this parameter to first trimester
screening. This study was integrated in a setting for first
trimester screening for Down syndrome (DS).
Methods
During a period of 13 months (January 9, 2003–February 26,
2004), an observational study was performed. All women with
singleton pregnancies who attended the department of Obstet-
rics and Prenatal Medicine of the Erasmus University Medical
Center for first trimester screening were informed about the
study. Patients were included in this study after giving oral
informed consent. Ultrasound examinations of 415 fetuses were
carried out between the 11 and 14 weeks’ gestation. Scans were
preformed with an ATL HDI-3000 ultrasound system (Advanced
Technology Laboratories, Seattle, WA, USA) either transvaginal-
ly, using a 7-MHz probe or abdominally, using a 5-MHz probe.
Gestational age was derived on the basis of the first day of the
last menstrual period (LMP) and confirmed by ultrasound
assessment of fetal biometry. The ultrasound examinationswere
carried out following the strict methodological criteria set by the
Fetal Medicine Foundation (FMF) w10, 12x. An experienced and
specially trained FMF-certified ultrasonographer (PH) conducted
all first trimester ultrasound examinations. The NT was meas-
ured in the mid-sagittal section of the fetus as the maximum
thickness of the subcutaneous translucency between the soft
tissue overlaying the cervical spine and the skin. The presence
and size of the jugular lymphatic sacs were investigated in a
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Table 1 Chromosomal abnormalities.
n Gestational age NT JLS left JLS right Test NT Test JLS
Trisomy 21 7 12q5 3.1 2.1 2.9 q q
12q1 4.5 1.4 1.7 q –
12q4 4.6 4.3 6.4 q q
13q0 4.8 1.9 2.4 q q
13q6 5.2 15.5 14.6 q q
13q2 5.7 0.0 0.0 q –
13q6 8.5 4.6 4.5 q q
Trisomy 18 3 11q2 5.3 6.6 6.1 q q
12q3 6.0 3.4 2.8 q q
13q4 4.3 1.7 1.3 q –
Trisomy 13 1 12q4 1.6 0.0 0.0 – –
Monosomy X 1 11q0 9.2 12.9 9.1 q q
47 XYY 1 12q2 2.0 1.9 1.7 – –
Figure 1 Transversal plane through the mandible (M) and spinal
cord (Sp). Bilateral normal size jugular lymphatic sac (JLS).
Measurement of JLS is done in an anterior-posterior direction.
transversal plane through the mandible and spinal cord and con-
firmed in sagittal and coronal planes, where feasible. Measure-
ments of the anterior-posterior size of the JLS were performed
in the transversal plane as shown in Figure 1. Digital recordings
of the first trimester screening and a transverse plane of the
neck, including mandible and spinal cord and the presence or
absence of the jugular lymphatic sacs, were collected for further
analysis. In all women, first trimester screening with additional
fetal biometry and visualization, measurement and documenta-
tion of jugular lymphatic sacs were completed within a time
frame of 30 min. Invasive procedures, i.e., transabdominal cho-
rionic villius sampling at 11–14 weeks’ gestation or amniocen-
tesis at 15–19 weeks’ gestation, were performed, where
indicated. Follow-up was obtained by means of questionnaires,
which were returned to us by the obstetrician or midwife super-
vising delivery.
Statistical analysis
If JLS could not be visualized, the size was set to zero. The non-
parametric Kendall’s Tau-b test, that takes ties into account, was
done to measure the association between NT and JLS size. In
the subset where JLS size is larger than zero, the Pearson cor-
relation coefficient between NT and the logarithm of JLS size
was determined.
Statistical significance was defined as a P-0.05. In the study
group the risk of chromosomal abnormalities was modelled
using binary logistic regression. Statistically significant effects
and interactions were identified by backward stepwise elimina-
tion using the likelihood ratio test. The probability criterion for
stepwise entry was set at 0.05 and for removal from the equation
at 0.1. The statistical analyses were performed using the SPSS
statistical package for Windows release 11.1 (SPSS Inc., Chi-
cago, IL).
Results
During the study period, a total of 415 women with a
viable singleton pregnancy were evaluated. Median
maternal age in the total study population was 36 years
(range 18–43 years). The study population was mainly
white, i.e., 95% Caucasian, 1.2% Asian and 3.8% Afro-
American. As a result of various pleas and reminders,
complete follow up was obtained in 406 women (study
group). In the latter group 13 chromosomal abnormalities
(3.2%) were detected, while adverse pregnancy outcome
(fetal loss, fetal death and neonatal death) was docu-
mented in 9 other cases (2.2%), as summarized in Tables
1 and 2.
NT was successfully evaluated in all fetuses. There
were no differences between the groups with regard to
maternal age, ethnicity and gestational age at examina-
tion. Median gestational age was 12q3 weeks (range,
11q0 weeks–13q6 weeks) and median CRL was
61.7 mm (range, 45–84 mm). After excluding the chro-
mosomal abnormalities and adverse pregnancy out-
come, a subset group of 384 (94.6%) women with an
uncomplicated pregnancy were included for final
analyses.
In this subset the 95th percentile for NT size was
2.5 mm. Women were therefore considered ‘‘test-posi-
tive’’ if the NT size was above this level. The JLS were
detectable in 23% (97/406) women of the study group.
In the same subset of 384 uncomplicated pregnancies
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Table 2 Adverse pregnancy outcome.
n Gestational age NT JLS left JLS right Test NT Test JLS
Early fetal loss (-20 weeks) 5 11q3 2.0 0.0 0.0 – –
13q5 1.0 0.0 0.0 – –
13q1 0.8 0.0 0.0 – –
13q6 1.0 0.0 0.0 – –
13q3 1.0 0.0 0.0 – –
Intra uterine fetal death 2 13q5* 3.8 0.0 0.0 q –
13q6 1.9 0.0 0.0 – –
Neonatal death 2 12q1 1.5 0.0 0.0 – –
13q5** 2.3 2.8 2.9 – q
*Second pregnancy. First pregnancy hydrops fetalis, TOP at 19 weeks.
**Complex heart defect.
Table 3 Binary logistic regression results for chromosomal abnormalities.
Threshold* (mm) Sensitivity (%) Specificity (%) Odds ratio 95% Confidence interval
JLS 2.0 62 95 3.81** 2.19 6.64
NT 2.5 85 95 5.53** 3.12 9.82
*Women were considered screened positive if the distance was above this level.
**Statistically significant at the level P-0.001.
Figure 2 Correlation between NT and the mean JLS in the sub-
set of the study group, where measured JLS size is larger than
zero: *, refers to the pregnancy with visible JLS and adverse
outcome due to the complex heart defect (Table 2); d, uncom-
plicated pregnancy outcome; s, chromosomal abnormality.
the 95th percentile for the mean left and right JLS size
was 2.0 mm. Women were therefore considered ‘‘test-
positive’’ if the JLS size was above this level. Median size
of detectable JLS size was 1.7 mm (range 0.7–15.5 mm).
Table 1 shows that in the group of chromosomal abnor-
malities, all seven fetuses with trisomy 21 tested positive
for NT and 5/7 for JLS. For trisomy 18, all fetuses also
tested positive for NT and 2/3 for JLS. The fetus with
monosomy X (Turner syndrome, TS) tested positive in
both tests. Because of hypoplasia of the lymphatic sys-
tem in fetuses with TS w17x, it is questionable whether
these should be included in our study. However, during
the ultrasound investigation, the karyotype was not yet
known to the investigator during the examination and the
septated hygroma colli was identified as an enlarged NT
accompanied with bilateral enlarged JLS. Although NT
can identify about 80% of the fetuses with trisomy 13 in
a regular first trimester screening program w13x, in our
study one fetus with Patau syndrome was tested nega-
tive by NT and JLS (Table 1). On ultrasound, however,
dextrocardia was observed, which classified the fetus as
at increased risk of chromosomal abnormality. An abnor-
mal karyotype of 47 XYY is not associated with enlarged
NT and was tested negative by both NT and JLS. In the
group of adverse pregnancy outcome (Table 2) post mor-
tem reports on the early fetal loss were not available. In
the study group of 406 fetuses, a significant non-para-
metric correlation (Kendall’s Tau-b, Rs0.129) was found
between NT and JLS (P-0.01). As shown in Figure 2,
the subset of fetuses in which the mean left and right
JLS size was larger than zero (ns97), showed a strong
correlation between NT and the logarithm of JLS. The
Pearson correlation coefficient was 0.636 and the P-val-
ue was highly significant (P-0.001). The binary regres-
sion results are shown in Table 3. In this study group, NT
in combination with maternal age and JLS did not con-
tribute to a statistically better prediction of chromosomal
abnormalities than NT alone. Moreover, as enlarged NT
and JLS are strongly interrelated, these parameters can-
not be considered independent and therefore not appli-
cable in a multiple parameter binary logistic regression
analysis. Although both NT and JLS parameters are sta-
tistically significant predictors, the sensitivity for NT was
better than for JLS.
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Discussion
This study was carried out to evaluate the prevalence of
JLS and was integrated in a setting of first trimester
screening for Down syndrome (DS) in order to evaluate
its value in screening for chromosomal abnormalities.
The association between NT, JLS and fetal outcome were
investigated, but in this context, the prerequisite for add-
ing JLS to first trimester measurement of NT should
be an independent association with chromosomal
abnormalities.
Nuchal translucency is a subcutaneous fluid accumu-
lation in the neck region of unknown origin. However,
Haak et al. w6, 7x showed that in mouse embryos with
trisomy 16 the development of the JLS preceded the NT
and that the JLS showed distension just prior to the
occurrence of the increased NT. This notion was sup-
ported by other investigators w1, 2, 4, 5x. Trisomy 16
mouse embryos are considered to be the animal model
for trisomy 21 in the human w8, 9, 11, 16x. The delayed
organization and connection of these JLS to the venous
circulation might explain the transient nature of the NT.
Human studies on NT and JLS w1–4, 6, 7x were unable
to give conclusive evidence on the question if JLS pre-
cedes NT or vice versa. It merely suggests that there
seems to be a fetus-specific pattern in the development
of the jugular lymphatic system, and therefore a unique
expanding phase of the jugular lymphatic sacs.
If the development of JLS in human fetuses is similar to
the animal model of the trisomy 16 mouse embryo w1, 2,
4–7x, further analysis might determine its possibility as an
early marker for chromosomal abnormalities before the
11th week of gestation. Considering the large number of
attrition of chromosomal abnormal pregnancies and preg-
nancies with major anomalies during the first trimester, this
additional value remains to be discussed. The absence of
JLS in early pregnancy could perhaps be used as a sono-
graphic marker for ruling out chromosomal abnormalities
(negative predictive value). In our study, the smallest JLS
size detectable by ultrasound was 0.7 mm, which approx-
imated the spatial resolution of the ultrasound equipment
in combination with the 7 MHz transvaginal and 5 MHz
(broadband) abdominal transducers. In fact, the ability to
detect JLS is limited by the spatial resolution of ultrasound
machines. Although one could hypothesize that improve-
ment of ultrasound imaging performance might improve
the visualization of small JLS, their potential additional val-
ue for the early detection of fetal chromosomal abnor-
malities merits further research. Nevertheless, the
sonographic visualization of JLS smaller than 2.0 mm is
time consuming and requires specially trained and highly
skilled ultrasound operators.
From our study we conclude that clearly visualized
JLS significantly predict chromosomal abnormalities,
although NT is a better predictor. In terms of test per-
formance, however, the additional value of combined
testing is limited as both predictors are interrelated.
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